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Clostridium difficile colitis in patients 
after kidney and pancreas-kidney 
transplantation 
Abstract: Limited data exist about Gostridium dijjicile colitis (CDC) in solid 
organ transplant patients. Bet ween 1/1/99 and 12/31/02.600 kidney and 102 
pancreas-kidney allograft recipients were transplanted. Thirty·nine (5.5°,,) of 
these patients had CDC on the hasis of clinical and laboratory fmdings. Of these 
39 patients, 35 have information available for review. CDC developed at a median 
of 30 days after transplantation, and the patients nndergoing pancreas-kidney 
transplantation had a slightly higher incidence of CDC than recipients of kidney 
alone (7.8% vs. 4.5%. P> 0.05). All but one patient presented with diarrhea. 
Twenty·four patients (64.9%) were diagnosed in the hospital. and CDC occurred 
during first hospitalization in 14 patients (40"'0). Treatment was with QI'al 
metronidazole (M) in 33 patients (94 %) and M + oral vancomycin (M + V) in 2 
patients. Eight patients had recurrent CDC, which occurred at a median of 30 days 
(range 15-314) after the first episode. Two patients (5.7%) developed fulminant 
CDC, presented with toxic megacolon, and underwent colectomy. One of them 
died; the other patient survived after colectomy. CDC shou ld be considered as a 
diagnosis in transplant patients with history of diarrhea after antibiotic use. and 
should be treated aggressively before the infection becomes complicated. 
Infections are the leading cause of morbidity and mortality in the early 
post-transplant period. More than 80% of recipients suffer at least one 
episode of infection in the first year (1. 2). The occurrence of infectious 
complications is closely related to immunosuppressive treatment. includ-
ing induction, maintenance, and the treatment of acute rejection. 
Although, many viral and bacterial opportunistic infections are well 
known in kidney and pancreas-kidney allograft recipients, Clostridium 
difficile colitis (CDC) is a less frequently described gastrointestinalmfec· 
tion in these patients. Clostridium difficile (CD) is one of the most common 
hospital-acquired (nosocomial) infections causing antibiotic-associated 
colitis (3). CDC has been defined as the existence of diarrhea and CD toxin 
in the stool. 
In this study, we identified our patients with CDC aiter kidney and 
pancreas-kidney transplantation and report the clinical presentation, 
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timing of infection. risk factors, recurrence, and treatment.We also report 
twu pat ients with fulminant CDC (FCDC) after kidney transplantation. 
Material and methods 
Between 1 January 1999 and 31 December 2002,702 adults underwent 
kidne)' and pancreas-kidney transplantation at University of Pittsburgh 
Ml·died Center. Of these, 600 were kidney alone and 102 patients were 
pancreas kidney allograft recipients. All patients with a diagnosis of 
CDC at discharge from hospital and with a positive assay for CD toxin 
in stool during this period were identified. A detailed computer-assisted 
chart review, through the University of Pittsburgh Medical Archive and 
Retrieval System (MARS) and the Electronic Data Interface for Trans-
plantation (EDIT) of the Thomas E. Starzl Transplantation Institute, 
was used to study the patients who had CDC during this period. Demo-
graphic features and the immunosuppressive regimen of all patients 
with CDC were reviewed. All patients' records were also evaluated for 
clinical presentation of the infection, fever, white blood cell count, history 
of antibiotic use in the past 1 month, recurrence of the infection, treat-
ment of the CDC, and presence of FCDC. 
Review was made of the clinical course, including laboratory values, 
dosage and trough levels of immunosuppressive agents, and steroid and 
antibody treatments for rejection episodes. Data were collected by two 
physicians (KK and LR).Thedatacollection was approved by the Institu-
tional Review Board (IRB) of the University of Pittsburgh Medical 
Center. 
Inlll1unosuppression was tacrolimus and mycophenolate mofetil and 
steroids in 12 patients; tacrolimus, sirolimus, and steroids in 3; tacrolimus 
and steroids in 6; and preconditioning (Thymoglobulin-14, Campath-1, 
Ol\T3-1) witb tacrolimus monotherapy in 14 patients (4). The initial treat-
ment of acute rejection was with a steroid bolus for patients receiving the 
preconditioning regimen and with a steroid bolus and recycle for tradi-
tionally immunosuppressed patients. Steroid-resistant acute rejections 
and high-grade rejections were treated with antibody therapy All kidney 
allograft recipients received cefazolin 1.0 g intraoperatively and on the 
first postoperative day. All pancreas-kidney allograft recipients re-
cei wd cefotetan 1.5 g intraoperatively and on the first 2 postoperative 
days. Pancreas-kidney recipients underwent preoperative bowel pre-
paration with enemas. All patients were started on oral nystatin (antifun-
gal). trimethoprim-sulfamethoxazole (for Pneumocystis carinit), and 
cytomegalovirus prophylaxis for 3-6 months. 
Treatment of CDC was with oral metronidazole for 15 days or until 
diarrhea subsided; oral vancomycin was added if metronidazole was 
not effective in controlling diarrhea. Recurrent CDC was also treated 
with metronidazole, and additional agents such as oral vancomycin, 
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cholestyramine, or intravenous immunoglobulin. Beginning in January 
2003, all kidney and pancreas-kidney transplant recipients have been 
prophylactically treated with metronidazole in the early post-tran:;plant 
period. 
Data are expressed as mean ± SD and median with a range for highlY 
skewed distributions. Parametric and non-parametric tests including 
Student's t-test,WIlcoxon signed rank test and X2 test were used as appro· 
priate. A probability value of P < 0.05 was considered as statistically sig 
nificant. Statistical analysis was done using SPSS for Wmdows version 
11.0 (Chicago, IL, USA). 
Results 
Among the 702 recipients, 39 (5.5%) patients were found to have CDC by 
laboratory and clinical findings. Thirty-five (mean age 53 ± 14 years. 26 
male, 9 females) patients have data available for review. Twenty-seven of 
them were kidney and 8 patients were pancreas-kidney allograft recipi· 
ents (Table 1). The etiology of renal failure was diabetes mellitus ill IS. 
chronic tubulointerstitial nephritis in 6, chronic glomerulonephritis ill 
4, unknown in 3, polycystic kidney disease in 3, hypertension in 2, and 
systemic lupus erythomatosus (SLE) in 2 patients. Nine patients uncleI" 
went living-related kidney transplantation, and 26 underwent cadaveric 
kidney and pancreas-kidney transplantation. Although, CDC was seen 
slightly more often in pancreas-kidney allograft recipients than in kid 
ney recipients (7.8% vs. 4.5%), the difference was not statistically signif· 
icant (P> 0.05). 
CDC occurred at a median of 30 days (range: 3 819) after transplanUI 
tion, and 75°/', of the cases manifested within 4 months after the opera· 
tion. CDC occurred during the initial hospitalization in 14 (4(]",,) patient:;. 
and 22 (62.9%) patients developed the infection as Inpatients. The main 
clinical presentation of CDC was with diarrhea, which occurred in all bu t 
one patient (97.1 %). Abdominal pain and fever (> 38.5 "C) were other al' 
companying symptoms seen in 16 (45.7%) and 4 (11.4 %) patients, respec· 
tively and one patient presented with ileus. Leukocytosis (> 10,0001 
mm:l) developed in 16 (45.7%) patients. FIfteen patients had a stool test 
for white blood cells, and only 2 (l3.3%) had white blood cells in the stool. 
As a risk factor, 31 (88.6 %) patients had a history of antibiotIc use in pre 
vious 1 month. The main treatment was with oral metronidazole in 33 
patients (94.3%) and with oral metronidazole and oral vancomyclll l!1 2 
patients (5.7%). The patients who had preconditiuning had a slightl1 
higher incidence of CDC than those not receiving preconditioning, but 
this difference was not statistically significant (7.3% vs. 4.2%, P> 0.05). 
Eight patients (22.9%) had recurrent infection (Table 2). The median time 
to recurrence was 30 days after the first episode of CDC (range: 15<)14), 
and most recurrences (75%) occurred within 40 days after the tirot 
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CDC in kidney and pancreas-kidney allograft recipients 
Incidence 
Age (mean ± SO) 
Sex (M/F) 
Antibody preconditioning 
Time to CDC after transplantation (median. range: min-max days) 
CDC occurrence during initial hospitalization 
Recurrent CDC 
Fulminant CDC 
Kidney (N = 27) 
4.5% 
54.1 ± 14.9 
19/8 
12/27 (44%) 
30(3-819) 
10/27(37%) 
7/27 (25%) 
2/27 (7.4%) 
Pancreas-kidney (N = 8) p 
7.8% NS 
50.0 ± 6.9 NS 
7/1 NS 
4/8 (50%) NS 
28 (10-520) NS 
4/8(50%) NS 
1/7 (12.5%) NS 
0% NS 
0% NS Death 2/27 (7.4%) -K------------------=-=D--=~c__------------------
CDC. Clostridium difflCile colitis; NS, not significant. 
Table 1 
Recurrent and non-recurrent CDC 
Age (mean ± SO) 
Sex (M/F) 
Cadaveric/living donor 
Kidney/pancreas-kidney 
Antibody preconditioning 
Steroid avoidance 
Time to CDC after transplantation (median, range: min-max days) 
Previous acute rejection 
CDC occurrence during initial hospitalization 
CDC, Clostridium difflCile colitis; NS. not significant. 
Table 2 
Patients with recurrent CDC (N = 8) 
54.8 ± 12.4 
6/2 
7/1 
7/1 
5/8(62.5%) 
5/8 (62.5%) 
20(11-819) 
4/8(50%) 
3/8(37.5%) 
Patients without recurrence (N = 27) P 
52.0 ± 14.0 illS 
20/7 NS 
19/8 NS 
20/7 NS 
10/27 (37%) NS 
11/27 (40.7%) NS 
43(3-690) NS 
14/27 (51.8%) NS 
11/27 (40.7%) NS 
episode. Six patients had 1 recurrent infection after the first episode, one transplant) died after operation. The pathological specimens of the colon 
patient had 2. and one had 5 recurrent episodes. All patients with recur- were consistent with necrotizing colitis secondary to CDC. 
rent infection presented with diarrhea. The treatment of recurrent dis- Since 1/1/03, only two (lJ %) cases of CDC have been observed in 178 
ease was with oral metronidazole in four, oral vancomycin in two, and transplant recipients (Table 3). These 178 patients received prophylactic 
oral metronidazole plus vancomycin in two patients. One patient devel- metronidazole in the early post-transplant period. 
oped chronic recurrent CDC and was treated with metronidazole plus 
vancomycin and additional cholestyramine and intravenous immuno-
globulin; however, the patient did not respond to treatment and ulti-
mately succumbed to inanition. )10 statistically significant difference 
was noted between the patients with primary and with recurrent CDC 
Clabl~ 2) 
Fulminant colitis developed in two kidney allograft recipients (5.7%) 
during their first episode of infection when they were in hospital. Both 
patients underwent colectomy for toxic megacolon. Fever and leukocyto-
sis (17.400/mm3, and 67,400/mm3 ) were the striking features in both pa-
tients. While one patient survived, the other (who had a previous liver 
12 Transplant Infectious Disease 2004: 6: 10-14 
Discussion 
CDC is a well-known nosocomial infection causing diarrhea, m()SI com-
monly secondary to antibiotic use. Although its incidence varies in ell (-
ferent centers, CDC has been reported to occur in 1-4"" of general 
surgery patients (5, 6). CDC can spread primarily by the fecal-oral route 
in hospitalized or nursing home patients and may cause severe morbid-
ity and mortality, especially in elderly hospitalized patients. In hospitalized 
CDC and fulminant CDC between 1999 and 2003 
Patients with CDC 
Patients with fulminant CDC 
Patients with recurrent CDC 
CDC episodes 
CDC. Clostridium difflCile colitis. 
Table 3 
1999N(%) 
6(3.1%) 
o 
2(33%) 
7 
2000N(%) 
5(3.3%) 
o 
2 E4M"~F 
6 
patients, CDC has been reported to be more frequent in general surgery 
patients than in other hospitalized patients, with an association between 
CDC and prior CD diarrhea, prior antibiotic treatment, renal insuffi-
ciency, recent hospitalization, age of patient, and length of total hospital 
stay (5, 6). In their study, West et al. (7) found that CDC is not an uncom-
mon infection in patients after kidney and pancreas-kidney transplan-
tation and reported an incidence of 8%. Pediatric patients (16%) and 
pancreas-kidney recipients (15.5%) had a higher incidence of CDC than 
kidney alone (3.5%) recipients (7). In our patients, the overall incidence 
was 5.5°,;). The incidence tended to be higher in patients receiving anti-
body preconditioning than in those who did not; however this difference 
was not statistically significant. 
FCDC refers to any patient with a systemic inflammatory syndrome 
(fever, hypotension, tachypnea, leukocytosis, and/or a requirement for 
volume resuscitation) that results in death or an illness severe enough 
that death is likely without urgent colectomy (8). However, it is unclear 
why some patients develop a fulminant course despite appropriate treat-
ment, while others do not. It may be related to the host's capability to 
mount an efficient antibody-mediated response to clostridial toxins. 
While West et al. (7) did not report any patient with FCDC, Dallal et al. 
(8) reported higher incidence of FCDC in lung allograft recipients. How-
ever, there are few reports about the occurrence of FCDC in kidney and 
pancreas-kidney transplantation. FCDC developed in two patients 
(5.7%) and one survived after colectomy. 
The time interval between transplantation and the development of 
CDC can vary considerably (7, 9, 10). We found that CDC occurred rela-
t ively early after transplantation (median 30 days) and within 4 months 
in 75°/" of our patients. West et al. (7) reported a significant difference in 
liming of the CDC in pediatric, adult kidney, and pancreas-kidney pa-
tients. Adult kidney allograft recipients developed CDC an average of 
Ei months after transplantation, while in pancreas-kidney recipients 
CDC occurred 6 months after the operation. In our patients, CDC oc-
curred at a similar time interval after kidney and pancreas-kidney 
transplantation; it occurred during the initial hospital stay in 40% of 
the patients and in a total of 62% of the patients during an in-hospital 
stay. West et al. (7) reported that 26% of the adult kidney and 54 % of 
the pancreas-kidney patients developed the infection during the initial 
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2001N(%) 
5(2.7%) 
1 
o 
5 
2002 N(%) 
19(10.6%) 
1 
4(21%) 
29 
2003N(%) 
2 (1.1%) 
o 
o 
2 
hospital stay. Nosocomial transmission, frequent antibiotic use, and Inl-
munosuppression may be factors leading to the occurrence ()f CDC iii the 
hospital. However, why some patients develop CDC, while others do not, 
and why some patients develop FCDC is not known. 
Hospitalization because of CDC has been reported to be increaseclll1 
recent years (8). The incidence of CDC in hospitalized patients increased 
from a baseline of 0.68% (1989-1999) to 1KOEF~I (20()O), and incidence of 
FCDC increased from 0°;;, (1990) to 3.2°/r, (2000). The mortality lor P;I-
tients diagnosed with CDC was 1PKR~oI and this is greater than the (JV(:rall 
hospital death rate of 3.4% (8). CDC thus increases mortality, even If It 
does not cause life-threatening complications such as toxic megacolon 
in most patients. In their study, Dallal et al. (8) found that CDC was qUite 
a common infection after lung transplantation; 78 (31 %) patients uut of 
250 were reported to have CDC between 1990 and 2000. Ten (13 '1;,) devel· 
oped FCDC, a significantly higher incidence than for other hospitalized 
patients (1.6 %). Although immunosuppression seems to be a risk factor 
for development of FCDC, immunosuppressed patients had a better sur-
vival (58% vs. 37%) after development of FCDC than non·immunosup· 
pressed patients. In our study, we found that adult kidney and pancreas 
kidney recipients had a 5,5% incidence of CDC during 1999 2002, and it 
was significantly higher than the overall incidence in our hospital 
(0.68%, P<O.OOl), Among kidney and pancreas-kidney allograft recipi· 
ents, 2 (5.7%) patients of 35 developed FCDC, which is higher than the 
1.6% overall incidence described by Dallal et al. (8), but it was lower than 
the lung allograft recipients (13%). Both of our patients with FCne un· 
derwent surgery, and one survived (50%). Regarding the higher inci· 
dence of CDC and FCDC after lung transplantation as compared to 
kidney and pancreas-kidney transplantation, it can be speculated thal 
longer hospital stay and more frequent antibiotic usage for repeated lung 
infection may be contributing factors. On the other hand, in their study, 
Dallal et al. (8) showed that patients with a prior history of successfully 
treated CDC seemed to be at highest risk for FCDC. In our study, both 
patients developed FCDC during their first episode of CDC. While West 
et al. (7) did not report any cases of FCDC in their kidney and pancreas-
kidney transplant recipients, Mistry et al. (9) and Altiparmak el al. (lO) 
reported one and two cases of FCDC in their kidney allograft recipients, 
respectively. 
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The treatment of FCDC is surgical, and total abdominal colectomy and 
ileostomy can be life saving; however, if the operation takes place after 
va so pressors are needed, the mortality rate increases significantly (7). 
Therefore, early recognition of FCDC is very important. In their study, 
Altiparmak et a!. (10) described two patients who developed FCDC; both 
died without surgical intervention. One patient survived after surgery 
for FCDC in the report of Mistry et a1. (9). Although data are limited, 
rCDC seems to be associated with a high mortality rate in kidney and 
pancreas- kidney allograft recipients. 
Several reasons are likely for the increased susceptibility to CDC 
among solid organ transplant patients, including the frequent use of 
antibiotics, suppression of anti-inflammatory cytokines, suppression of 
antibody-mediated response to toxins, and longer and more frequent 
hospital admissions. Although no data have shown any association be-
tween specific immunosuppressive agents and CDC infection, we found 
that the patients receiving antibody induction might be more prone to 
develop CDC than those not receiving antibody induction; however, this 
difference was not statistically significant. In addition to host and envi-
ronmental factors, recent antibiotic use is one of the well-known risk fac-
lOrs for CDC. In our study, we found that CDC was associated with cur-
rent antibiotic use in 31 patients (88%), while West et al. (7) reported that 
60% of the cases with CDC were related to antibiotic use. Despite appro-
priate treatment, it has been reported that the recurrence rate in non-im-
munosuppressed patients varies between 10% and 30%; West et a1. 
reported a 13% incidence of recurrent CDC in their pancreas-kidney pa-
tients. We found a 22.8% incidence of recurrent CDC. No statistically sig-
nificant differences were found between kidney and pancreas-kidney 
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